The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia.

Animals Apoptosis / genetics Heterografts Humans Leukemia, Myeloid, Acute / enzymology Mice Mutation Myeloid Progenitor Cells / metabolism Oxidative Phosphorylation Pyruvate Dehydrogenase Acetyl-Transferring Kinase / genetics fms-Like Tyrosine Kinase 3 / genetics

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
01 03 2022
Historique:
received: 13 06 2021
accepted: 08 02 2022
entrez: 2 3 2022
pubmed: 3 3 2022
medline: 13 4 2022
Statut: epublish

Résumé

Acute myeloid leukemia remains difficult to treat due to strong genetic heterogeneity between and within individual patients. Here, we show that Pyruvate dehydrogenase kinase 1 (PDK1) acts as a targetable determinant of different metabolic states in acute myeloid leukemia (AML). PDK1

Identifiants

DOI: 10.1038/s41467-022-28737-3 PMID: 35232995 PMC: PMC8888573
pubmed: 35232995
doi: 10.1038/s41467-022-28737-3
pii: 10.1038/s41467-022-28737-3
pmc: PMC8888573
doi:

Substances chimiques

PDK1 protein, human 0
Pyruvate Dehydrogenase Acetyl-Transferring Kinase 0
fms-Like Tyrosine Kinase 3 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1105

Informations de copyright

© 2022. The Author(s).

Références

Miller, C. A., Wilson, R. K. & Ley, T. J. Genomic landscapes and clonality of de novo AML. N. Engl. J. Med. 369, 1473 (2013).
pubmed: 24106950 pmcid: 4374653
Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
pubmed: 22817890 pmcid: 3407563 doi: 10.1016/j.cell.2012.06.023
Ley, T. J. et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
pubmed: 23634996 doi: 10.1056/NEJMoa1301689
Corces-Zimmerman, M. R., Hong, W. J., Weissman, I. L., Medeiros, B. C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl Acad. Sci. USA 111, 2548–2553 (2014).
pubmed: 24550281 pmcid: 3932921 doi: 10.1073/pnas.1324297111
Jan, M. & Majeti, R. Clonal evolution of acute leukemia genomes. Oncogene 32, 135–140 (2013).
pubmed: 22349821 doi: 10.1038/onc.2012.48
Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014).
pubmed: 24522528 pmcid: 4991939 doi: 10.1038/nature13038
de Boer, B. et al. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell 34, 674–689 (2018). e678.
pubmed: 30245083 doi: 10.1016/j.ccell.2018.08.014
Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361 (2011).
pubmed: 21160474 doi: 10.1038/nature09650
Klco, J. M. et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379–392 (2014).
pubmed: 24613412 pmcid: 3983786 doi: 10.1016/j.ccr.2014.01.031
Hughes, A. E. et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet. 10, e1004462 (2014).
pubmed: 25010716 pmcid: 4091781 doi: 10.1371/journal.pgen.1004462
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
pubmed: 13298683 doi: 10.1126/science.123.3191.309
Filippi, M. D. & Ghaffari, S. Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities. Blood 133, 1943–1952 (2019).
pubmed: 30808633 pmcid: 6497515 doi: 10.1182/blood-2018-10-808873
Hao, X. et al. Metabolic imaging reveals a unique preference of symmetric cell division and homing of leukemia-initiating cells in an endosteal niche. Cell Metab. 29, 950–965 (2019). e956.
pubmed: 30581117 doi: 10.1016/j.cmet.2018.11.013
Simsek, T. et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 7, 380–390 (2010).
pubmed: 20804973 pmcid: 4159713 doi: 10.1016/j.stem.2010.07.011
Vannini, N. et al. Specification of haematopoietic stem cell fate via modulation of mitochondrial activity. Nat. Commun. 7, 13125 (2016).
pubmed: 27731316 pmcid: 5064016 doi: 10.1038/ncomms13125
Vannini, N. et al. The NAD-booster nicotinamide riboside potently stimulates hematopoiesis through increased mitochondrial clearance. Cell Stem Cell 24, 405–418 (2019). e407.
pubmed: 30849366 doi: 10.1016/j.stem.2019.02.012
Yu, W. M. et al. Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation. Cell Stem Cell 12, 62–74 (2013).
pubmed: 23290137 pmcid: 3632072 doi: 10.1016/j.stem.2012.11.022
Ito, K. et al. Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance. Science 354, 1156–1160 (2016).
pubmed: 27738012 pmcid: 5164878 doi: 10.1126/science.aaf5530
de Almeida, M. J., Luchsinger, L. L., Corrigan, D. J., Williams, L. J. & Snoeck, H. W. Dye-independent methods reveal elevated mitochondrial mass in hematopoietic stem cells. Cell Stem Cell 21, 725–729 (2017). e724.
pubmed: 29198942 pmcid: 5728653 doi: 10.1016/j.stem.2017.11.002
Bonora, M., Ito, K., Morganti, C., Pinton, P. & Ito, K. Membrane-potential compensation reveals mitochondrial volume expansion during HSC commitment. Exp. Hematol. 68, 30–37 (2018). e31.
pubmed: 30395909 pmcid: 6350772 doi: 10.1016/j.exphem.2018.10.012
Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12, 446–451 (2006).
pubmed: 16565722 doi: 10.1038/nm1388
Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013).
pubmed: 23333149 pmcid: 3595363 doi: 10.1016/j.stem.2012.12.013
Khan, N. et al. Normal hematopoietic progenitor subsets have distinct reactive oxygen species, BCL2 and cell-cycle profiles that are decoupled from maturation in acute myeloid leukemia. PLoS ONE 11, e0163291 (2016).
pubmed: 27669008 pmcid: 5036879 doi: 10.1371/journal.pone.0163291
Jones, C. L. et al. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood 134, 389–394 (2019).
pubmed: 31101624 pmcid: 6659257 doi: 10.1182/blood.2019898114
Adane, B. et al. The hematopoietic oxidase NOX2 regulates self-renewal of leukemic stem cells. Cell Rep. 27, 238–254 (2019). e236.
pubmed: 30943405 pmcid: 6931909 doi: 10.1016/j.celrep.2019.03.009
Jones, C. L. et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell 34, 724–740 (2018). e724.
pubmed: 30423294 pmcid: 6280965 doi: 10.1016/j.ccell.2018.10.005
Seneviratne, A. K. et al. The mitochondrial transacylase, tafazzin, regulates for AML stemness by modulating intracellular levels of phospholipids. Cell Stem Cell 24, 621–636 (2019). e616.
pubmed: 30930145 pmcid: 7137093 doi: 10.1016/j.stem.2019.02.020
Anso, E. et al. The mitochondrial respiratory chain is essential for haematopoietic stem cell function. Nat. Cell Biol. 19, 614–625 (2017).
pubmed: 28504706 pmcid: 5474760 doi: 10.1038/ncb3529
Takubo, K. et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell 12, 49–61 (2013).
pubmed: 23290136 pmcid: 6592822 doi: 10.1016/j.stem.2012.10.011
Klimmeck, D. et al. Proteomic cornerstones of hematopoietic stem cell differentiation: distinct signatures of multipotent progenitors and myeloid committed cells. Mol. Cell Proteom. 11, 286–302 (2012).
doi: 10.1074/mcp.M111.016790
Halvarsson, C., Eliasson, P. & Jönsson, J.-I. Pyruvate dehydrogenase kinase 1 is essential for transplantable mouse bone marrow hematopoietic stem cell and progenitor function. PLoS ONE 12, e0171714 (2017).
pubmed: 28182733 pmcid: 5300157 doi: 10.1371/journal.pone.0171714
Chen, W. L. et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood 124, 1645–1654 (2014).
pubmed: 25006128 pmcid: 5726328 doi: 10.1182/blood-2014-02-554204
Gregory, M. A. et al. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Exp. Hematol. 58, 52–58 (2017).
pubmed: 28947392 pmcid: 5815916 doi: 10.1016/j.exphem.2017.09.007
de Jonge, H. J. et al. Gene expression profiling in the leukemic stem cell-enriched CD34(+) fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia 25, 1825–1833 (2011).
pubmed: 21760593 doi: 10.1038/leu.2011.172
Bagger, F. O. et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 44, D917–D924 (2016).
pubmed: 26507857 doi: 10.1093/nar/gkv1101
Rardin, M. J., Wiley, S. E., Naviaux, R. K., Murphy, A. N. & Dixon, J. E. Monitoring phosphorylation of the pyruvate dehydrogenase complex. Anal. Biochem. 389, 157–164 (2009).
pubmed: 19341700 pmcid: 2713743 doi: 10.1016/j.ab.2009.03.040
Korotchkina, L. G. & Patel, M. S. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J. Biol. Chem. 276, 37223–37229 (2001).
pubmed: 11486000 doi: 10.1074/jbc.M103069200
Qin, L. et al. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth. Oncotarget 7, 1395–1407 (2015).
pmcid: 4811468 doi: 10.18632/oncotarget.6366
Antonelli, A. et al. Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches. Blood 128, 2949–2959 (2016).
pubmed: 27733356 doi: 10.1182/blood-2016-05-719021
Carretta, M. et al. Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models. Exp. Hematol. 51, 36–46 (2017).
pubmed: 28456746 doi: 10.1016/j.exphem.2017.04.008
Huang, Q. et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J. Biol. Chem. 293, 3535–3545 (2018).
pubmed: 29317493 pmcid: 5846160 doi: 10.1074/jbc.M117.810101
Qin, L. et al. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth. Oncotarget 7, 1395–1407 (2016).
pubmed: 26593251 doi: 10.18632/oncotarget.6366
Jayavelu, A. K., Moloney, J. N., Bohmer, F. D. & Cotter, T. G. NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML. Exp. Hematol. 44, 1113–1122 (2016).
pubmed: 27666490 doi: 10.1016/j.exphem.2016.08.008
Stanicka, J., Russell, E. G., Woolley, J. F. & Cotter, T. G. NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells. J. Biol. Chem. 290, 9348–9361 (2015).
pubmed: 25697362 pmcid: 4392242 doi: 10.1074/jbc.M113.510495
Sallmyr, A. et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 111, 3173–3182 (2008).
pubmed: 18192505 doi: 10.1182/blood-2007-05-092510
Wierenga, A. T. J. et al. HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells. Cancer Metab. 7, 11 (2019).
pubmed: 31890203 pmcid: 6935105 doi: 10.1186/s40170-019-0206-y
Gallipoli, P. et al. Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood 131, 1639–1653 (2018).
pubmed: 29463564 doi: 10.1182/blood-2017-12-820035
Gregory, M. A. et al. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Exp. Hematol. 58, 52–58 (2018).
pubmed: 28947392 doi: 10.1016/j.exphem.2017.09.007
Baccelli, I. et al. Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia. Cancer Cell 36, 84–99 (2019). e88.
pubmed: 31287994 doi: 10.1016/j.ccell.2019.06.003
Xie, S. Z. et al. Sphingolipid modulation activates proteostasis programs to govern human hematopoietic stem cell self-renewal. Cell Stem Cell 25, 639–653 (2019). e637.
pubmed: 31631013 pmcid: 6838675 doi: 10.1016/j.stem.2019.09.008
Groen, R. W. et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 120, e9–e16 (2012).
pubmed: 22653974 doi: 10.1182/blood-2012-03-414920
Sontakke, P. et al. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model. Leukemia 30, 2064–2073 (2016).
pubmed: 27125308 doi: 10.1038/leu.2016.108
Fellmann, C. et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 5, 1704–1713 (2013).
pubmed: 24332856 doi: 10.1016/j.celrep.2013.11.020
Kohlmann, A. et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br. J. Haematol. 142, 802–807 (2008).
pubmed: 18573112 pmcid: 2654477 doi: 10.1111/j.1365-2141.2008.07261.x
Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res. 49, D325–D334 (2021).
doi: 10.1093/nar/gkaa1113
Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25–29 (2000).
pubmed: 10802651 pmcid: 3037419 doi: 10.1038/75556
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102

Auteurs

Ayşegül Erdem (A)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
Department of Biochemistry and Molecular Biology, Faculty of Biology, Avinguda Diagonal 643, 08028, Barcelona, Spain.

Silvia Marin (S)

Department of Biochemistry and Molecular Biology, Faculty of Biology, Avinguda Diagonal 643, 08028, Barcelona, Spain.
CIBER of Hepatic and Digestive Diseases (CIBEREHD), Institute of Health Carlos III, 28029, Madrid, Spain.
Institute of Biomedicine of University of Barcelona, 08028, Barcelona, Spain.
ORCID: 0000-0003-0693-2207

Diego A Pereira-Martins (DA)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
Hematology Division, LIM31, Faculdade de Medicina, University of São Paulo, São Paulo, SP, Brazil.

Roldán Cortés (R)

Department of Biochemistry and Molecular Biology, Faculty of Biology, Avinguda Diagonal 643, 08028, Barcelona, Spain.

Alan Cunningham (A)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

Maurien G Pruis (MG)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

Bauke de Boer (B)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

Fiona A J van den Heuvel (FAJ)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

Marjan Geugien (M)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

Albertus T J Wierenga (ATJ)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

Annet Z Brouwers-Vos (AZ)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

Eduardo M Rego (EM)

Hematology Division, LIM31, Faculdade de Medicina, University of São Paulo, São Paulo, SP, Brazil.

Gerwin Huls (G)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.

Marta Cascante (M)

Department of Biochemistry and Molecular Biology, Faculty of Biology, Avinguda Diagonal 643, 08028, Barcelona, Spain.
CIBER of Hepatic and Digestive Diseases (CIBEREHD), Institute of Health Carlos III, 28029, Madrid, Spain.
Institute of Biomedicine of University of Barcelona, 08028, Barcelona, Spain.
ORCID: 0000-0002-2062-4633

Jan Jacob Schuringa (JJ)

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. j.j.schuringa@umcg.nl.
ORCID: 0000-0001-8452-8555

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Régions du corps › Transplants › Hétérogreffes › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système hématopoïétique › Cellules de la moelle osseuse › Cellules souches hématopoïétiques › Progéniteurs myéloïdes › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Métabolisme › Phosphorylation › Phosphorylation oxydative › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Pyruvate dehydrogenase acetyl-transferring kinase › The Glycolytic Gatekeeper PDK1 defines...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Tyrosine kinase-3 de type fms › The Glycolytic Gatekeeper PDK1 defines...